FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287162242> ?p ?o ?g. }

• W2287162242 endingPage "16461" @default.
• W2287162242 startingPage "16445" @default.
• W2287162242 abstract "// Wei Xie 1, * , Fang Liu 1, * , Youfu Wang 1 , Xueyan Ren 1 , Tong Wang 1 , Zhiguo Chen 1 , Mingying Tang 1 , Fumou Sun 1 , Zhaoting Li 1 , Min Wang 1 , Juan Zhang 1 1 State Key Laboratory of Natural Medicines, School of Life Science & Technology, China Pharmaceutical University, Nanjing, China * These authors should be considered as joint first authors Correspondence to: Juan Zhang, e-mail: juancpu@126.com Min Wang, e-mail: minwang@cpu.edu.cn Keywords: antibody fusion protein, VEGFR2, MICA, anti-angiogenesis, immunosurveillance Received: August 25, 2015     Accepted: January 29, 2016     Published: February 19, 2016 ABSTRACT Binding of MHC class I-related chain molecules A and B (MICA/B) to the natural killer (NK) cell receptor NK group 2, member D (NKG2D) is thought critical for activating NK-mediated immunosurveillance. Angiogenesis is important for tumor growth and interfering with angiogenesis using the fully human IgG1 anti-VEGFR2 (vascular endothelial growth factor receptor 2) antibody (mAb04) can be effective in treating malignancy. In an effort to make mAb04 more effective we have generated a novel antibody fusion protein (mAb04-MICA) consisting of mAb04 and MICA. We found that mAb04-MICA maintained the anti-angiogenic and antineoplastic activities of mAb04, and also enhanced immunosurveillance activated by the NKG2D pathway. Moreover, in human breast tumor-bearing nude mice, mAb04-MICA demonstrated superior anti-tumor efficacy compared to combination therapy of mAb04 + Docetaxel or Avastin + Docetaxel, highlighting the immunostimulatory effect of MICA. In conclusion, mAb04-MICA provided new inspiration for anti-tumor treatment and had prospects for clinical application." @default.
• W2287162242 created "2016-06-24" @default.
• W2287162242 creator A5015102287 @default.
• W2287162242 creator A5042940004 @default.
• W2287162242 creator A5045703368 @default.
• W2287162242 creator A5061074158 @default.
• W2287162242 creator A5070141658 @default.
• W2287162242 creator A5072269850 @default.
• W2287162242 creator A5073362919 @default.
• W2287162242 creator A5073630988 @default.
• W2287162242 creator A5074656546 @default.
• W2287162242 creator A5083455588 @default.
• W2287162242 creator A5085025467 @default.
• W2287162242 date "2016-02-19" @default.
• W2287162242 modified "2023-09-24" @default.
• W2287162242 title "VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer" @default.
• W2287162242 cites W1207631117 @default.
• W2287162242 cites W1541232837 @default.
• W2287162242 cites W1551006141 @default.
• W2287162242 cites W1554682485 @default.
• W2287162242 cites W1573363574 @default.
• W2287162242 cites W1577687167 @default.
• W2287162242 cites W1589583253 @default.
• W2287162242 cites W1595098530 @default.
• W2287162242 cites W1875554126 @default.
• W2287162242 cites W1969950463 @default.
• W2287162242 cites W1972814015 @default.
• W2287162242 cites W1979226579 @default.
• W2287162242 cites W1981851073 @default.
• W2287162242 cites W1985576417 @default.
• W2287162242 cites W1993786192 @default.
• W2287162242 cites W1996408493 @default.
• W2287162242 cites W1999420561 @default.
• W2287162242 cites W2014349052 @default.
• W2287162242 cites W2018311806 @default.
• W2287162242 cites W2022069273 @default.
• W2287162242 cites W2022414765 @default.
• W2287162242 cites W2026895645 @default.
• W2287162242 cites W2032341321 @default.
• W2287162242 cites W2039970555 @default.
• W2287162242 cites W2045568207 @default.
• W2287162242 cites W2056645320 @default.
• W2287162242 cites W2061084780 @default.
• W2287162242 cites W2064920472 @default.
• W2287162242 cites W2069203677 @default.
• W2287162242 cites W2072607744 @default.
• W2287162242 cites W2081972352 @default.
• W2287162242 cites W2082849642 @default.
• W2287162242 cites W2084868385 @default.
• W2287162242 cites W2092285890 @default.
• W2287162242 cites W2103637402 @default.
• W2287162242 cites W2106273338 @default.
• W2287162242 cites W2112887207 @default.
• W2287162242 cites W2120372745 @default.
• W2287162242 cites W2122080125 @default.
• W2287162242 cites W2126945850 @default.
• W2287162242 cites W2135568473 @default.
• W2287162242 cites W2137162822 @default.
• W2287162242 cites W2139691488 @default.
• W2287162242 cites W2141436376 @default.
• W2287162242 cites W2141643004 @default.
• W2287162242 cites W2142661589 @default.
• W2287162242 cites W2143171862 @default.
• W2287162242 cites W2145539398 @default.
• W2287162242 cites W2145761690 @default.
• W2287162242 cites W2146974347 @default.
• W2287162242 cites W2153297361 @default.
• W2287162242 cites W2157000170 @default.
• W2287162242 cites W2157769714 @default.
• W2287162242 cites W2167172107 @default.
• W2287162242 cites W4249144791 @default.
• W2287162242 doi "https://doi.org/10.18632/oncotarget.7501" @default.
• W2287162242 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4941327" @default.
• W2287162242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26909862" @default.
• W2287162242 hasPublicationYear "2016" @default.
• W2287162242 type Work @default.
• W2287162242 sameAs 2287162242 @default.
• W2287162242 citedByCount "15" @default.
• W2287162242 countsByYear W22871622422017 @default.
• W2287162242 countsByYear W22871622422018 @default.
• W2287162242 countsByYear W22871622422019 @default.
• W2287162242 countsByYear W22871622422020 @default.
• W2287162242 countsByYear W22871622422021 @default.
• W2287162242 countsByYear W22871622422022 @default.
• W2287162242 crossrefType "journal-article" @default.
• W2287162242 hasAuthorship W2287162242A5015102287 @default.
• W2287162242 hasAuthorship W2287162242A5042940004 @default.
• W2287162242 hasAuthorship W2287162242A5045703368 @default.
• W2287162242 hasAuthorship W2287162242A5061074158 @default.
• W2287162242 hasAuthorship W2287162242A5070141658 @default.
• W2287162242 hasAuthorship W2287162242A5072269850 @default.
• W2287162242 hasAuthorship W2287162242A5073362919 @default.
• W2287162242 hasAuthorship W2287162242A5073630988 @default.
• W2287162242 hasAuthorship W2287162242A5074656546 @default.
• W2287162242 hasAuthorship W2287162242A5083455588 @default.
• W2287162242 hasAuthorship W2287162242A5085025467 @default.
• W2287162242 hasBestOaLocation W22871622421 @default.
• W2287162242 hasConcept C109316439 @default.

• next